Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum

Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum Tumour angiogenesis factor (TAF) has been extracted from a variety of animal and human tumours. Its ability to induce neovascularization in two bioassays, viz. rat air‐sac and chick chorio‐allantoic membrane, is demonstrated. Similar extracts from normal tissues fail to induce angiogenesis. TAF extracts have been used to raise a xenogeneic antiserum, the specificity of which was investigated using classical immunological methods. Its ability to neutralize the biological activity of TAF using the two in vivo assays, was also demonstrated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Cancer Wiley

Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum

International Journal of Cancer , Volume 23 (1) – Jan 15, 1979

Loading next page...
 
/lp/wiley/tumour-angiogenesis-factor-taf-and-its-neutralisation-by-a-xenogeneic-1813ecMCul

References (22)

Publisher
Wiley
Copyright
Copyright © 1979 Wiley‐Liss, Inc., A Wiley Company
ISSN
0020-7136
eISSN
1097-0215
DOI
10.1002/ijc.2910230115
Publisher site
See Article on Publisher Site

Abstract

Tumour angiogenesis factor (TAF) has been extracted from a variety of animal and human tumours. Its ability to induce neovascularization in two bioassays, viz. rat air‐sac and chick chorio‐allantoic membrane, is demonstrated. Similar extracts from normal tissues fail to induce angiogenesis. TAF extracts have been used to raise a xenogeneic antiserum, the specificity of which was investigated using classical immunological methods. Its ability to neutralize the biological activity of TAF using the two in vivo assays, was also demonstrated.

Journal

International Journal of CancerWiley

Published: Jan 15, 1979

There are no references for this article.